Cognitive and mood side effects of lower urinary tract medication

References

• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–1315.
   PubMed Web of Science ®Google Scholar
• Michel MC, Mehlburger L, Bressel HU, et al. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does comorbidity alter tolerability? J Urol. 1998;160(3):784–791.
   PubMed Web of Science ®Google Scholar
• Schneider T, Marschall-Kehrel D, Hanisch JU, et al. Do gender, age or life style factors affect responses to anti-muscarinic treatment in overactive bladder patients? Int J Clin Pract. 2010;64(9):1287–1293.
   PubMed Web of Science ®Google Scholar
• DuBeau CE, Kraus SR, Griebling TL, et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. J Urol. 2014;191(2):395–404.
   PubMed Web of Science ®Google Scholar
• Farrall AJ, Wardlaw JM. Blood-brain-barrier: ageing and microvascular disease: systematic review and meta-analysis. Neurobiol Aging. 2009;30(3):337–352.
   PubMed Web of Science ®Google Scholar
• Klausner AP, Steers WD. Antimuscarinics for the treatment of overactive bladder: a review of central nervous system effects. Curr Bladder Dysfunct Rep. 2008;3:161–167.
   Google Scholar
• Kraus SR, Bavendam T, Brake T, et al. Vulnerable elderly patients and overactive bladder syndrome. Drugs Aging. 2010 September 01;27(9):697–713.
   PubMed Web of Science ®Google Scholar
• Pagoria D, O’Connor RC, Guralnick ML. Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients. Curr Urol Rep. 2011 October 01; 12(5):351–357.
   PubMedGoogle Scholar
• Wagg A. Choosing oral drug therapy for overactive bladder in older people. Expert Opin Pharmacother. 2018 August 13;19(12):1375–1380.
   PubMed Web of Science ®Google Scholar
• Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80(2):209–220.
   PubMed Web of Science ®Google Scholar
• Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. Br Med J. 2006;332(7539):455–458.
   PubMed Web of Science ®Google Scholar
• Fox C, Smith T, Maidment I, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43(5):604–615.
   PubMed Web of Science ®Google Scholar
• Sink KM, Thomas J 3rd, Xu H, et al. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc. 2008;56(5):847–853.
   PubMed Web of Science ®Google Scholar
• Nye AM, Clinard V, Barnes C. Medication nonadherence secondary to drug-induced memory loss. Consult Pharm. 2010;25(2):117–121.
   PubMedGoogle Scholar
• Chancellor MB. What happened when I took OAB drugs? Neurourol Urodyn. 2007;26(7):1057.
   PubMed Web of Science ®Google Scholar
• Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol. 2001;41(6):636–644.
   PubMed Web of Science ®Google Scholar
• Kay GG, Staskin DR, MacDiarmid S, et al. Cognitive effects of oxybutynin chloride topical gel in older healthy subjects: a 1-week, randomized, double-blind, placebo and active-controlled study. Clin Drug Investig. 2012;32(10):707–714.
   PubMed Web of Science ®Google Scholar
• Wesnes KA, Edgar C, Tretter RN, et al. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Safety. 2009 November 01;8(6):615–626.
   PubMed Web of Science ®Google Scholar
• Diefenbach K, Donath F, Maurer A, et al. Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin Drug Investig. 2003;23(6):395–404.
   PubMed Web of Science ®Google Scholar
• Diefenbach K, Arold G, Wollny A, et al. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged >50 years. BJU Int. 2005;95:346–349.
   PubMed Web of Science ®Google Scholar
• Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol. 2006;50(2):317–326.
   PubMed Web of Science ®Google Scholar
• Kay GG, Wesnes KA. Pharmacodynamic effects of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int. 2005;96(7):1055–1062.
   PubMed Web of Science ®Google Scholar
• Golding JF, Wesnes KA, Leaker BR. The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance & cognitive function. Br J Clin Pharmacol. 2018;84(7):1535–1543.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol. 2005;173(2):493–498.
   PubMed Web of Science ®Google Scholar
• Kay GG, Maruff P, Scholfield D, et al. Evaluation of cognitive function in healthy older subjects treated with fesoterodine. Postgrad Med. 2012 May 01;124(3):7–15.
   PubMed Web of Science ®Google Scholar
• Morrow SA, Rosehart H, Sener A, et al. Anti-cholinergic medications for bladder dysfunction worsen cognition in persons with multiple sclerosis. J Neurol Sci. 2018;385:39–44.
   PubMed Web of Science ®Google Scholar
• Krebs J, Scheel-Sailer A, Oertli R, et al. The effects of antimuscarinic treatment on the cognition of spinal cord injured individuals with neurogenic lower urinary tract dysfunction: a prospective controlled before-and-after study. Spinal Cord. 2017 August 08 online;56:22.
   PubMed Web of Science ®Google Scholar
• Moga DC, Carnahan RM, Lund BC, et al. Risks and benefits of bladder antimuscarinics among elderly residents of veterans affairs community living centers. J Am Med Dir Assoc. 2013;14(10):749–760.
   PubMed Web of Science ®Google Scholar
• Moga DC, Abner EL, Wu Q, et al. Bladder antimuscarinics and cognitive decline in elderly patients. Alzheimers Dement. 2017;3(1):139–148.
   Google Scholar
• Kosilov K, Kuzina I, Loparev S, et al. Influence of the short-term intake of high doses of solifenacin and trospium on cognitive function and health-related quality of life in older women with urinary incontinence. Int Neurourol J. 2018 3;22(1):41–50.
   PubMed Web of Science ®Google Scholar
• Monnot M, Ross E. Urinary urgency medications may compromise discrete rather than global cognitive skills. Dement Geriatr Cogn Dis Extra. 2012;2(1):238–247.
   PubMedGoogle Scholar
• Giramonti KM, Kogan BA, Halpern LF. The effects of anticholinergic drugs on attention span and short-term memory skills in children. Neurourol Urodyn. 2008;27(4):315–318.
   PubMed Web of Science ®Google Scholar
• Ferrara P, D’Aleo CM, Tarquini E, et al. Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida. BJU Int. 2001;87(7):674–678.
   PubMed Web of Science ®Google Scholar
• Sommer BR, O’Hara R, Askari N, et al. The effect of oxybutynin tratment on cognition in children with diurnal incontinence. J Urol. 2005;173(6):2125–2127.
   PubMed Web of Science ®Google Scholar
• Lackner TE, Wyman JF, McCarthy TC, et al. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc. 2008;56(5):862–870.
   PubMed Web of Science ®Google Scholar
• Wagg A, Dale M, Tretter R, et al. Randomised, multicenre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol. 2013;64(1):74–81.
   PubMed Web of Science ®Google Scholar
• Esin E, Ergen A, Cankurtaran M, et al. Influence of antimuscarinic therapy on cognitive functions and quality of life in geriatric patients treated for overactive bladder. Aging Ment Health. 2015 March 04;19(3):217–223.
   PubMed Web of Science ®Google Scholar
• Sakakibara R, Tateno F, Yano M, et al. Imidafenacin on bladder and cognitive function in neurologic OAB patients. Clin Auton Res. 2013 August 01;23(4):189–195.
   PubMed Web of Science ®Google Scholar
• Kosilov K, Loparev S, Ivanoskaya M, et al. A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron. Arch Gerontol Geriatr. 2015;61(2):212–216.
   PubMed Web of Science ®Google Scholar
• Kosilov K, Kuzina I, Kuznetsov V, et al. Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage. Aging Male. 2018 April 03;21(2):121–129.
   PubMed Web of Science ®Google Scholar
• Burger M, Betz D, Hampel C, et al. Efficacy and tolerability of solifenacin in men with overactive bladder: results of an observational study. World J Urol. 2014 August 01;32(4):1041–1047.
   PubMed Web of Science ®Google Scholar
• Hampel C, Betz D, Burger M, et al. Solifenacin in the elderly: results of an observational study measuring efficacy, tolerability and cognitive effects. Urol Int. 2017;98(3):350–357.
   PubMed Web of Science ®Google Scholar
• Geller EJ, Dumond JB, Bowling JM, et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Med Reconstr Surg. 2017;23:118–123.
   PubMed Web of Science ®Google Scholar
• Geller EJ, Crane AK, Wells EC, et al. Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women. Clin Drug Investig. 2012;32(10):697–705.
   PubMed Web of Science ®Google Scholar
• Ferreira-Vieira TH, Guimaraes IM, Silva FR, et al. Alzheimer’s disease: targeting the cholinergic system. Curr Neuropharmacol. 2016;14(1):101–115.
   PubMed Web of Science ®Google Scholar
• Risacher SL, McDonald BC, Tallman EF, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol. 2016;73(6):721–732.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Maruyama S, Ito Y, et al. Effect of oxybutynin and imidafenacin on central muscarinic receptor occupancy and cognitive function: a monkey PET study with [11C](+)3-MPB. Neuroimage. 2011 September 01;58(1):1–9.
   PubMed Web of Science ®Google Scholar
• Jakobsen SM, Kersten H, Molden E. Evaluation of brain anticholinergic activities of urinary spasmolytic drugs using a high-throughput radio receptor bioassay. J Am Geriatr Soc. 2011;59(3):501–505.
   PubMed Web of Science ®Google Scholar
• Callegari E, Malhotra B, Bungay PJ, et al. A comprehensive nonclinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol. 2011;72(2):235–246.
   PubMed Web of Science ®Google Scholar
• Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride is undetectable in the older human central nervous system. J Am Geriatr Soc. 2010;58(8):1618–1619.
   PubMed Web of Science ®Google Scholar
• Oki T, Kageyama A, Takagi Y, et al. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. J Urol. 2007;177(2):766–770.
   PubMed Web of Science ®Google Scholar
• Maruyama S, Tsukada H, Nishiyama S, et al. In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment. J Pharmacol Exp Ther. 2008;325(3):774–781.
   PubMed Web of Science ®Google Scholar
• Cappon GD, Bush B, Newgreen D, et al. Tolterodine does not affect memory assessed by passive-avoidance response test in mice. Eur J Pharmacol. 2008 January 28;579(1):225–228.
   PubMed Web of Science ®Google Scholar
• Oka T, Nakano K, Kirimoto T, et al. Effects of antimuscarinic drugs on both urinary frequency and cognitive impairment in conscious, nonrestrained rats. Jpn J Pharmacol. 2001;87(1):27–33.
   PubMedGoogle Scholar
• Kobayashi F, Yageta Y, Yamazaki T, et al. Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Arzneimittelforschung. 2007 21.12.2011;57(03):147–154.
   PubMedGoogle Scholar
• Ali AK, Heran BS, Etminan M. Persistent sexual dysfunction and suicidal ideation in young men treated with low-dose finasteride: a pharmacovigilance study. Pharmacother J Human Pharmacol Drug Ther. 2015;35(7):687–695.
   Google Scholar
• Fertig R, Shapiro J, Bergfeld W, et al. Investigation of the plausibility of 5-alpha-reductase inhibitor syndrome. Skin Appendage Disord. 2017;2(3–4):120–129.
   PubMed Web of Science ®Google Scholar
• Welk B, McArthur E, Ordon M, et al. Association of suicidality and depression with 5α-reductase inhibitors. JAMA Int Med. 2017;177(5):683–691.
   PubMed Web of Science ®Google Scholar
• Altomare G, Capella GL. Depression circumstantially related to the administration of finasteride for androgenetic alopecia. J Dermatol. 2002;29(10):665–669.
   PubMed Web of Science ®Google Scholar
• Rahimi-Ardabili B, Pourandarjani R, Habibollahi P, et al. Finasteride induced depression: a prospective study. BMC Clin Pharmacol. 2006 October 07;6(1):7.
   PubMedGoogle Scholar
• Trost L, Saitz TR, Hellstrom WJG. Side effects of 5‐alpha reductase inhibitors: a comprehensive review. Sex Med Rev. 2013 May 01; 1(1):24–41.
   PubMedGoogle Scholar
• Unger JM, Till C, Thompson JIM, et al. Long-term consequences of finasteride vs placebo in the prostate cancer prevention trial. JNCI. 2016;108(12):djw168–djw68.
   PubMedGoogle Scholar
• Welk B, McArthur E, Ordon M, et al. The risk of dementia with the use of 5 alpha reductase inhibitors. J Neurol Sci. 2017;379:109–111.
   PubMed Web of Science ®Google Scholar
• Finn DA, Beadles-Bohling AS, Beckley, EH, et al. A new look at the 5α-reductase inhibitor finasteride. CNS Drug Rev. 2006;12(1):53–76.
   PubMedGoogle Scholar
• Diviccaro S, Giatti S, Borgo F, et al. Treatment of male rats with finasteride, an inhibitor of 5alpha-reductase enzyme, induces long-lasting effects on depressive-like behavior, hippocampal neurogenesis, neuroinflammation and gut microbiota composition. Psychoneuroendocrinology. 2019;99:206–215.
   PubMed Web of Science ®Google Scholar
• Giatti S, Foglio B, Romano S, et al. Effects of subchronic finasteride treatment and withdrawal on neuroactive steroid levels and their receptors in the male rat brain. Neuroendocrinology. 2016;103(6):746–757.
   PubMed Web of Science ®Google Scholar
• Caruso D, Abbiati F, Giatti S, et al. Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma. J Steroid Biochem Mol Biol. 2015 February 01;146:74–79.
   PubMed Web of Science ®Google Scholar
• Cecchin E, De Mattia E, Mazzon G, et al. A pharmacogenetic survey of androgen receptor (CAG)N and (GGN)N polymorphisms in patients experiencing long term side effects after finasteride discontinuation. Int J Biol Markers. 2014;29(4):310–316.
   PubMed Web of Science ®Google Scholar
• Roberto Cosimo M, Livio C, Marco M, et al. Altered methylation pattern of the SRD5A2 gene in cerebrospinal fluid of post-finasteride patients: a pilot study. Endocr Connect. 2019;in press:EC-19–0199.
   Google Scholar
• Barrett-Connor E, von Mühlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo study. J Clin Endocrinol Metab. 1999;84(2):573–577.
   PubMed Web of Science ®Google Scholar
• Oelke M, Gericke A, Michel MC. Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. Expert Opin Drug Safety. 2014;29(1):1–11.
   Google Scholar
• Duan Y, Grady JJ, Albertsen PC, et al. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. Pharmacoepidemiol Drug Saf. 2018;27(3):340–348.
   PubMed Web of Science ®Google Scholar
• Tae BS, Jeon BJ, Choi H, et al. Alpha-blocker and risk of dementia in patients with benign prostate hyperplasia: a nationwide population-based study using the National Health Insurance Service database. J Urol. 2019;202(2):362–368.
   PubMed Web of Science ®Google Scholar
• Doze VA, Papay RS, Goldenstein BL, et al. Long-term α1A-adrenergic receptor stimulation improves synaptic plasticity, cognitive function, mood, and longevity. Mol Pharmacol. 2011;80(4):747–758.
   PubMed Web of Science ®Google Scholar
• Doze VA, Handel EM, Jensen KA, et al. α1A- and α1B-adrenergic receptors differentially modulate antidepressant-like behavior in the mouse. Brain Res. 2009 August 18;1285:148–157.
   PubMed Web of Science ®Google Scholar
• Szot P, White SS, Greenup JL, et al. Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: evidence of compensatory changes. Neuroscience. 2007 March 25;146(1):471–480.
   PubMed Web of Science ®Google Scholar
• Taguchi K, Schäfers RF, Michel MC. Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. Br J Clin Pharmacol. 1998;45:49–55.
   PubMed Web of Science ®Google Scholar
• Franco-Salinas G, de la Rosette JJMCH, Michel MC. Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral-controlled absorption system formulations. Clin Pharmacokinet. 2010;49(3):177–188.
   PubMed Web of Science ®Google Scholar
• Nikolic K, Filipic S, Smolinski A, et al. Partial least square and hierarchical clustering in ADMET modeling: prediciton of blood-brain barrier permeation of a adrenergic and imidazoline receptor ligands. J Pharm Pharm Sci. 2013;16(4):622–647.
   PubMed Web of Science ®Google Scholar
• Stemmelin J, Cohen C, Terranova JP, et al. Stimulation of the ß3-adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology. 2008;33(3):574–587.
   PubMed Web of Science ®Google Scholar
• Irwig MS. Depressive symptoms and suicidal thoughts among former useres of finasteride with persistent sexual side effects. J Clin Psychiatry. 2012;73(9):1220–1223.
   PubMed Web of Science ®Google Scholar
• Wagg AS, Cardozo L, Chapple C, et al. Overactive bladder syndrome in older people. BJU Int. 2007;99(3):502–509.
   PubMed Web of Science ®Google Scholar
• Wagg A, Verdejo C, Molander U. Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder. Int J Clin Pract. 2010;64(9):1279–1286.
   PubMed Web of Science ®Google Scholar
• De Roeck EE, De Deyn PP, Dierckx E, et al. Brief cognitive screening instruments for early detection of Alzheimer’s disease: a systematic review. Alzheimers Res Ther. 2019 February 28;11(1):21.
   PubMedGoogle Scholar
• Triantafylidis LK, Clemons JS, Peron EP, et al. Brain over bladder: a systematic review of dual cholinesterase inhibitor and urinary anticholinergic use. Drugs Aging. 2018 January 01;35(1):27–41.
   PubMed Web of Science ®Google Scholar
• Salvatore S, Serati M, Cardozo L, et al. Cognitive dysfunction with tolterodine use. Am J Obstet Gynecol. 2007;197(2):e8–e8.
   PubMed Web of Science ®Google Scholar
• Shiota T, Torimoto K, Momose H, et al. Temporary cognitive impairment related to administration of newly developed anticholinergic medicines for overactive bladder: two case reports. BMC Res Notes. 2014;7:672.
   PubMedGoogle Scholar
• Krege S, Kinzig-Schppers M, Sörgel F, et al. Absorption of intravesically applied drugs: comparison of normal and ileal-augmented rabbit bladder. J Urol. 2004;172(5 Pt 1):2045–2050.
   PubMed Web of Science ®Google Scholar
• Maggiore ULR, Salvatore S, Alessandri F, et al. Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. Expert Opin Drug Metab Toxicol. 2012;8(11):1387–1408.
   PubMed Web of Science ®Google Scholar
• Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Int Med. 2015;175(3):401–407.
   PubMed Web of Science ®Google Scholar
• Oelke M, Becher K, Castro-Diaz D, et al. Appropriateness of oral drugs for long-term treatment ofl ower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing. 2015;44(5):745–755.
   PubMed Web of Science ®Google Scholar
• American Urogynecologic Society Guidelines Committee. AUGS consensus statement: Association of Anticholinergic Medication Use and Cognition in Women with Overactive Bladder. Female Pelvic Med Reconstr Surg. 2017;23(3):177–178.
   PubMed Web of Science ®Google Scholar
• Womack KB, Heilman KM. Tolterodine and memory. Dry but forgetful. Arch Neurol. 2003;60(5):771–773.
   PubMedGoogle Scholar
• Jewart RD, Green J, Lu C-J, et al. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. Am J Geriatric Psychiatry. 2005 March 01;13(4):324–328.
   PubMed Web of Science ®Google Scholar
• Ganzer CA, Jacobs AR. Emotional consequences of finasteride: fool’s gold. Am J Men’s Health. 2018;12(1):90–95.
   PubMed Web of Science ®Google Scholar
• Ganzer CA, Jacobs AR, Iqbal F. Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms. Am J Men’s Health. 2015;9(3):222–228.
   PubMed Web of Science ®Google Scholar
• Madersbacher S, Michel MC. Re: tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. Eur Urol. 2018;74(4):522–523.
   PubMed Web of Science ®Google Scholar
• Ulrich S. Differential prescription behavior in benign prostatic syndrome may explain relationship found between tamsulosin and dementia. Pharmacoepidemiol Drug Saf. 2018;27(11):1157–1158.
   PubMed Web of Science ®Google Scholar
• Füllhase C, Chapple C, Cornu JN, et al. Systematic review of combination of drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol. 2013;64(2):228–243.
   PubMed Web of Science ®Google Scholar
• van Dijk MM, de la Rosette JJMCH, Michel MC. Effects of α1-adrenoceptor antagonists on male sexual function. Drugs. 2006;66(3):287–301.
   PubMed Web of Science ®Google Scholar
• Becher KF, Madersbacher S, Michel MC. Beeinflussen Medikamente gegen das benigne Prostatasyndrom Stimmung oder Kognition? Der Urologe. 2019 March 01;58(3):248–253.
   PubMedGoogle Scholar